person
Pierre O.
- Country
- France
- Department
- Nuclear Medicine
Research Overview
assignment
10
Clinical Trials ·
- A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of [177Lu]LU-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer
- Phase I/II Study of [225Ac]Ac-PSMA-R2 in Metastatic Hormone-Sensitive and Castration-Resistant Prostate Cancer with/without Prior 177Lu-PSMA Therapy
- Evaluation of [18F]PSMA-1007 PET/CT Imaging for Detecting Pelvic Nodal Metastases in High-Risk Prostate Cancer Patients
location_city
3
Research Sites
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
56
Sites with multiple studies
Has run more than one trial at 56 of 99 partner sites.
Specializations
Advanced Prostate Cancer Management
This investigator specializes in treating various stages of prostate cancer, with particular focus on metastatic conditions including both hormone-sensitive and castration-resistant forms.
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Neuroendocrine Prostate Cancer
Radioligand Therapy Expertise
The investigator works extensively with targeted radioligand therapies, particularly focusing on PSMA-targeted treatments and novel radiopharmaceutical approaches.
- Lutetium-177 Based Treatments
- Actinium-225 Applications
- Multi-Target Radioligand Therapy
Diagnostic Innovation
The investigator employs advanced diagnostic imaging techniques for cancer detection and monitoring, with expertise in various PET/CT applications.
- PSMA-Based Imaging
- Copper-64 PSMA Scanning
- Gallium-68 Diagnostics
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.